Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
JAMA Oncology|December 30, 2020
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized TrialKevin Kalinsky, Fangxin Hong, Carolyn K McCourt, et al.
Journal of the National Cancer Institute|July 16, 2026
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007)Yara Abdou, Jess Hoag, William E Barlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 7, 2017
Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab GovitecanJhanelle E Gray, Rebecca S Heist, Alexander N Starodub, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
Journal of the National Cancer Institute|December 10, 2024
Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trialYara Abdou, William E Barlow, Julie R Gralow, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 24, 2021
Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter ExperienceSeth A Wander, Hyo S Han, Mark L Zangardi, et al.
The New England Journal of Medicine|April 21, 2021
Sacituzumab Govitecan in Metastatic Triple-Negative Breast CancerAditya Bardia, Sara A Hurvitz, Sara M Tolaney, et al.
Research Square|February 23, 2026
Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trialAmrita Basu, Saumya Umashankar, Michelle Melisko, et al.
Nature Communications|January 11, 2024
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsGail D Lewis, Guangmin Li, Jun Guo, et al.
Pageof 16